Nature Communications · 2022 · 38 citations · 60 references
MedicineMolecular GeneticsOncologyCancer GeneticsMolecular OncologyOncogenesCancer BiomarkersCancer EpigeneticsColorectal CancerMalignant NeoplasmsOncogenic Signaling PathwaysSignal Transduction In CancerCetuximab TherapyEgfr DependenceEgfr InhibitionEpidermal Growth Factor Receptor InhibitionMapk Pathway MutationsPredictive Biomarker AssessmentPredictive Biomarker DevelopmentPredictive Biomarker Discovery
Most colorectal (CRC) tumors are dependent on EGFR/KRAS/BRAF/MAPK signaling activation. ARID1A is an epigenetic regulator mutated in approximately 5% of non-hypermutated CRC tumors. Here we show that anti-EGFR but not anti-VEGF treatment enriches for emerging ARID1A mutations in CRC patients. In addition, we find that patients with ARID1A mutations, at baseline, are associated with worse outcome when treated with cetuximab- but not bevacizumab-containing therapies; thus, this suggests that ARID1A mutations may provide both an acquired and intrinsic mechanism of resistance to anti-EGFR therapies. We find that, ARID1A and EGFR-pathway genetic alterations are mutually exclusive across lung and colorectal cancers, further supporting a functional connection between these pathways. Our results not only suggest that ARID1A could be potentially used as a predictive biomarker for cetuximab treatment decisions but also provide a rationale for exploring therapeutic MAPK inhibition in an unexpected but genetically defined segment of CRC patients.
60
The Molecular Signatures Database Hallmark Gene Set Collection
Arthur Liberzon, Chet Birger, Helga Thorvaldsdóttir et al. · Cell Systems · 2015 · 14.5K citations · Full text
Comprehensive molecular characterization of human colon and rectal cancer
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan, Shannon J. Turley, Dorothee Nickles et al. · Nature · 2018 · 5.5K citations
Life Sciences, Immunology, Oncology +16